Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

The agency says it has taken various steps to ensure the privacy of participants’ data. 

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

The publicly available database found nearly a third of samples included mutations targeted by either approved drugs or therapies in clinical trials. 

The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.

Brexit's effect on science, melding disciplines, and more

January 2016's selection of notable quotes

The National Cancer Institute is launching a Phase 2 trial matching patients with specific mutations to drugs tailored to those genetic changes.